PML related to number of Tysabri infusions, FDA says
18 September 2009
Katie McQue
Please Login to read the full article.
18 September 2009
Katie McQue
katie.mcque@informa.com
The US
FDA has received reports of two further cases of the rare and potentially fatal brain infection, progressive multifocal encephalopathy (PML), in multiple sclerosis patients receiving
Biogen Idec's Tysabri (natalizumab), bumping the number of confirmed cases up to 13. However, it is not...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Biogen reports 10 more Tysabri PML cases including four deaths
- Novartis's misfortunes with Gilenya could provide a boost for other MS drug makers
- FDA permits Biogen, Elan to add anti-JC virus status in Tysabri label
- US FDA delays decision on adding anti-JC virus status in Tysabri label
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
